Clonidine

How to order Clonidine

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Clonidine on Prescriptsy

Clonidine is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Clonidine is a centrally-acting alpha-2 adrenergic agonist that has been used in clinical practice since the 1960s.

In the United Kingdom, it is licensed for the treatment of hypertension, the prophylaxis of migraine and vascular headaches, and the management of menopausal flushing (hot flushes and night sweats).

Clonidine works by reducing the activity of the sympathetic nervous system, which lowers blood pressure, decreases heart rate, and modulates the vasomotor instability responsible for menopausal symptoms.

Although newer antihypertensive agents have largely replaced clonidine as a first-line treatment for high blood pressure, it retains specific roles in clinical practice, particularly for patients who have not responded to or cannot tolerate first-line agents, and for the management of menopausal flushing in women for whom hormone replacement therapy (HRT) is contraindicated or not preferred.

This page provides a comprehensive clinical overview of clonidine, covering its mechanism of action, licensed indications, dosing, side effects, the critical warning about rebound hypertension on withdrawal, and how to obtain a prescription in the UK.

Important safety information about clonidine

Before reading further, note the following critical safety points about clonidine.

• Do not stop clonidine suddenly. Abrupt withdrawal can cause rebound hypertension, which may be severe and potentially life-threatening. Always follow your prescriber's tapering schedule when discontinuing treatment.
• Clonidine causes drowsiness and sedation. Do not drive or operate machinery until you know how the medicine affects you.
• Alcohol increases the sedative and blood-pressure-lowering effects of clonidine and should be limited or avoided.
• If you are taking a beta-blocker alongside clonidine and both need to be stopped, the beta-blocker must be withdrawn first, followed by gradual clonidine taper.

What is hypertension

Hypertension (high blood pressure) is a chronic condition in which the force of blood against the artery walls is consistently elevated.

It is defined as a sustained clinic blood pressure of 140/90 mmHg or higher, or an ambulatory or home blood pressure average of 135/85 mmHg or higher (NICE NG136).

Hypertension is one of the most common cardiovascular risk factors in the UK, affecting approximately 1 in 3 adults, and is a major contributor to stroke, heart attack, heart failure, chronic kidney disease, and vascular dementia.

Most cases of hypertension in the UK are primary (essential) hypertension, meaning there is no single identifiable cause.

Risk factors include age, family history, excess salt intake, obesity, physical inactivity, excess alcohol consumption, and chronic stress.

Secondary causes (including renal artery stenosis, phaeochromocytoma, Cushing syndrome, and primary aldosteronism) account for a small minority of cases and should be considered in resistant or young-onset hypertension.

Place of clonidine in hypertension management

NICE NG136 recommends a stepwise approach to antihypertensive treatment, starting with ACE inhibitors or ARBs (Step 1), adding calcium channel blockers or thiazide-like diuretics (Steps 2 and 3), and considering spironolactone, alpha-blockers, or beta-blockers at Step 4 for resistant hypertension.

Clonidine is not included in the standard NICE pathway but may be considered as an adjunctive or alternative agent for patients who remain hypertensive despite optimised multi-drug therapy, or who have specific contraindications to first-line agents.

Its use in hypertension management in the UK is typically guided by specialist input.

What is migraine prophylaxis

Migraine is a complex neurological condition affecting approximately 1 in 7 people globally.

It is characterised by recurrent episodes of moderate to severe headache, often unilateral and pulsating, accompanied by nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).

Prophylactic (preventive) treatment is considered when migraines occur frequently (typically 4 or more days per month), are severe, or significantly impair quality of life.

NICE CKS on migraine lists several prophylactic options including propranolol, topiramate, and amitriptyline as first-line choices.

Clonidine is listed in the BNF as a licensed option for migraine prophylaxis but is not a first-line recommendation.

It may be considered when first-line agents are contraindicated, not tolerated, or ineffective. An 8-week trial is typically recommended to assess efficacy before deciding whether to continue treatment.

What are menopausal flushes

Hot flushes and night sweats (collectively known as vasomotor symptoms) are the hallmark symptoms of the menopause, experienced by approximately 75 to 80% of women during the menopausal transition.

They result from altered thermoregulatory function in the hypothalamus, triggered by declining oestrogen levels.

Episodes last from a few seconds to several minutes and may occur multiple times per day, disrupting sleep, concentration, and quality of life.

HRT remains the most effective treatment for menopausal vasomotor symptoms.

However, HRT is contraindicated or not preferred in some women, including those with a history of oestrogen-receptor-positive breast cancer, venous thromboembolism, or active liver disease.

Clonidine provides a non-hormonal alternative for these patients.

NICE NG23 (Menopause: diagnosis and management) notes that clonidine may be offered for vasomotor symptoms when HRT is not appropriate, though it acknowledges that the evidence for its efficacy is limited and it may provide only modest benefit.

How clonidine works: mechanism of action

Clonidine is an imidazoline derivative that acts primarily on alpha-2 adrenergic receptors in the brainstem, specifically in the nucleus tractus solitarius and the locus coeruleus.

Stimulation of these presynaptic receptors reduces sympathetic nervous system outflow from the central nervous system to the heart, blood vessels, and kidneys.

The resulting physiological effects include reduced heart rate (negative chronotropy), decreased cardiac output, reduced peripheral vascular resistance, and lower blood pressure.

In the context of migraine prophylaxis, clonidine is thought to act by stabilising vascular tone and modulating noradrenergic neurotransmission, reducing the abnormal cerebrovascular reactivity that contributes to migraine pathogenesis.

For menopausal flushing, clonidine is believed to act on the hypothalamic thermoregulatory centre, reducing the noradrenergic signalling that triggers inappropriate vasodilation and sweating.

Clonidine is well absorbed orally, with bioavailability of approximately 75 to 100%. Peak plasma concentrations are reached within 1 to 3 hours.

The elimination half-life is 6 to 20 hours (average approximately 12 hours), supporting twice or three times daily dosing.

It is partly metabolised by the liver and partly excreted unchanged by the kidneys. Dose adjustment may be required in patients with significant renal impairment.

Clinical evidence and guidelines

The antihypertensive efficacy of clonidine has been established in clinical trials dating from the 1970s.

While it effectively lowers blood pressure, its side effect profile (sedation, dry mouth, rebound hypertension on withdrawal) has limited its place in modern hypertension guidelines, which favour agents with better tolerability and cardiovascular outcome data (ACE inhibitors, ARBs, calcium channel blockers, thiazide-like diuretics).

The BNF continues to list clonidine for hypertension but notes that its role is as an adjunct to other antihypertensives rather than a first-line treatment.

For migraine prophylaxis, evidence from randomised controlled trials shows mixed results. Some trials demonstrated modest reductions in migraine frequency, while others found no significant benefit compared with placebo.

The BNF retains the indication, but NICE does not include clonidine among its recommended first-line migraine prophylactic agents.

A pragmatic 8-week treatment trial is appropriate to assess individual response.

For menopausal flushing, clinical trials have shown that clonidine reduces the frequency of hot flushes by approximately 1 to 2 episodes per day compared with placebo, which is a modest effect compared with HRT.

NICE NG23 acknowledges clonidine as an option when HRT is not appropriate and advises that patients should be informed about the likely degree of benefit and the potential side effects.

Dosage and administration

Hypertension

The usual starting dose is 50 to 100 micrograms three times daily. The dose is titrated upwards at weekly intervals based on blood pressure response and tolerability.

The usual maintenance dose is 300 to 1200 micrograms daily in divided doses. The maximum recommended dose is 1200 micrograms per day.

Regular blood pressure monitoring is essential during dose titration.

Migraine prophylaxis

The recommended dose is 50 micrograms twice daily, which may be increased to 75 micrograms twice daily if there is no adequate response after 2 weeks.

Treatment should be assessed after 8 weeks. If meaningful benefit has not been achieved, clonidine should be withdrawn gradually.

Menopausal flushing

The usual dose is 50 to 75 micrograms twice daily. Treatment is typically started at the lower dose and increased if needed based on symptom response. The effectiveness should be reviewed after 2 to 4 weeks.

General dosing advice

Clonidine tablets should be swallowed with water and can be taken with or without food.

The last dose of the day is often given at bedtime, which can help manage the sedative side effect.

If a dose is missed, take it as soon as remembered, but skip it if the next dose is due soon. Never take a double dose.

Abrupt cessation must be avoided in all indications; your prescriber will provide a gradual tapering schedule.

Side effects of clonidine

Very common and common side effects

Drowsiness and sedation are the most frequently reported adverse effects, affecting a significant proportion of patients, particularly during the first 1 to 2 weeks of treatment or following dose increases.

Tolerance to sedation often develops with continued use, but some patients remain affected throughout treatment.

Dry mouth is reported by approximately 40% of patients and can be managed with frequent sips of water, sugar-free gum, or saliva substitutes.

Other common effects include dizziness, headache, fatigue, constipation, and nausea.

Uncommon side effects

Postural hypotension occurs particularly in elderly patients and when clonidine is combined with other blood-pressure-lowering agents. Patients should rise slowly from sitting or lying positions.

Depression, sleep disturbance, vivid dreams, and reduced libido have been reported.

Fluid retention and peripheral oedema may occur and can usually be managed with dose adjustment or the addition of a diuretic.

Bradycardia (slow heart rate) and Raynaud's phenomenon (cold, numb, or discoloured fingers and toes) reflect the reduction in sympathetic tone.

Rare side effects

Atrioventricular block, hallucinations, gynaecomastia (breast enlargement in men), and elevated blood glucose have been reported rarely. Skin reactions including rash, pruritus, and urticaria are uncommon with oral formulations.

Rebound hypertension

Although not a side effect of the drug itself, rebound hypertension following abrupt withdrawal is the most clinically significant adverse event associated with clonidine.

It typically occurs 18 to 72 hours after the last dose and is characterised by rapid blood pressure elevation, tachycardia, headache, agitation, tremor, and diaphoresis.

It is discussed in detail in the warnings section below.

When to seek medical advice

Contact your GP or NHS 111 if you experience persistent dizziness, fainting, unusually slow or irregular heartbeat, mood changes or depression, significant swelling of the ankles, or any sign of allergic reaction.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Rebound hypertension on withdrawal

This is the single most important safety consideration with clonidine.

Abrupt cessation of clonidine, particularly at higher doses (above 600 micrograms per day) or after prolonged use, can trigger a rebound surge in sympathetic activity, causing severe hypertension, tachycardia, headache, agitation, tremor, and sweating.

In rare cases, hypertensive encephalopathy or stroke has been reported. Treatment should always be discontinued by gradual dose reduction over 2 to 4 days.

If other antihypertensive agents (particularly beta-blockers) are being taken concurrently, the beta-blocker must be withdrawn first, as beta-blockade can exacerbate rebound hypertension by preventing compensatory vasodilation.

Patients should be clearly informed about this risk and should not stop treatment without medical guidance.

Driving and operating machinery

Clonidine impairs alertness and reaction time, particularly at the start of treatment and during dose escalation.

Patients should be advised not to drive or operate machinery until they are confident that their mental performance is not affected.

The DVLA should be consulted regarding driving fitness if sedation is persistent.

Concurrent medications

Clonidine interacts with several drug classes. Central nervous system depressants (including benzodiazepines, opioids, and alcohol) may potentiate sedation. Tricyclic antidepressants may reduce the antihypertensive effect of clonidine.

Non-steroidal anti-inflammatory drugs (NSAIDs) may also attenuate the blood-pressure-lowering effect. Your prescriber should review all concurrent medications before starting clonidine.

Renal impairment

Approximately 40 to 60% of clonidine is excreted unchanged by the kidneys. Patients with significant renal impairment may require dose reduction and enhanced monitoring of blood pressure and side effects.

Pregnancy and breastfeeding

Clonidine crosses the placenta and is excreted in breast milk. It should be used during pregnancy only if the expected benefit to the mother justifies the potential risk.

Breastfeeding is not recommended during clonidine treatment. If clonidine is used near delivery, the neonate should be monitored for hypotension and other effects of alpha-2 agonist exposure.

How to get a clonidine prescription in the UK

Clonidine is a prescription-only medicine (POM) in the UK. For hypertension, it is usually prescribed by a GP or cardiologist after first-line antihypertensive agents have been tried.

For migraine prophylaxis, your GP or neurologist may initiate a trial of clonidine if first-line agents are unsuitable.

For menopausal flushing, your GP or menopause specialist may prescribe clonidine when HRT is contraindicated or not preferred.

Authorised online prescribers registered with the GPhC may also issue prescriptions following appropriate clinical assessment.

The NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with the conditions clonidine treats

Pharmacological treatment is most effective when combined with appropriate lifestyle modifications.

For hypertension, these include reducing salt intake to less than 6 g per day, maintaining a healthy weight, taking regular physical activity (at least 150 minutes of moderate-intensity exercise per week), limiting alcohol intake, stopping smoking, and managing stress.

For migraine, keeping a headache diary to identify triggers, maintaining regular sleep patterns, staying hydrated, and managing stress are all recommended alongside prophylactic medication.

For menopausal symptoms, regular exercise, maintaining a cool sleeping environment, wearing layered clothing, reducing caffeine and alcohol intake, and cognitive behavioural therapy (CBT) may all help alongside pharmacological treatment.

When to seek urgent medical advice

Seek urgent medical advice or call 999 if you experience sudden severe headache with blood pressure significantly higher than your normal readings (possible rebound hypertension), chest pain, signs of stroke (sudden weakness or numbness on one side, difficulty speaking, vision changes), or severe allergic reaction (facial swelling, difficulty breathing, widespread rash).

Contact your GP or NHS 111 for any new or worsening symptoms during treatment. Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Clonidine Hydrochloride Tablets - Summary of Product Characteristics (EMC)
• Clonidine hydrochloride - British National Formulary (BNF)
• NICE NG136: Hypertension in adults
• NICE NG23: Menopause: diagnosis and management
• NICE CKS: Migraine
• High blood pressure - NHS
• MHRA Yellow Card Scheme